With 0.9 million shares changed hands, the volume of the stock remained lighter than its average volume of 7.59 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.85 whereas the lowest price it dropped to was $0.812. The 52-week range on ICU shows that it touched its highest point at $6.90 and its lowest point at $0.31 during that stretch. It currently has a 1-year price target of $2.00. Beta for the stock currently stands at -0.99.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ICU was up-trending over the past week, with a rise of 6.63%, but this was up by 16.89% over a month. Three-month performance dropped to -33.10% while six-month performance fell -53.65%. The stock lost -57.24% in the past year, while it has lost -83.44% so far this year. A look at the trailing 12-month EPS for ICU yields -2.45 with Next year EPS estimates of -0.46. For the next quarter, that number is -0.15. This implies an EPS growth rate of 88.39% for this year and 40.26% for next year.
Float and Shares Shorts:
At present, 27.91 million ICU shares are outstanding with a float of 26.61 million shares on hand for trading. On 2025-07-31, short shares totaled 2.07 million, which was 917.0 higher than short shares on 1751241600. In addition to Mr. Eric Schlorff as the firm’s CEO, President & Executive Director, Mr. David A. Green CPA, M.B.A. serves as its Chief Financial Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, ICU reported revenue of $338000.0 and operating income of -$1756000.0. Over the past year, revenue came in at $0.00 while operating income stood at -$4.32M. It generated -$2002000.0 net income for the quarter, which came to -$4.33M over the last twelve months. The EBITDA in the recently reported quarter was -$2009000.0 and diluted EPS was -$0.18. EBITDA for the full year was -$4.32M.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With ICU analysts setting a high price target of 2.0 and a low target of 2.0, the average target price over the next 12 months is 2.0. Based on these targets, ICU could surge 140.96% to reach the target high and rise by 140.96% to reach the target low. Reaching the average price target will result in a growth of 140.96% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$7.75 being high and -$7.75 being low. For ICU, this leads to a yearly average estimate of -$7.75. The surprise factor in the prior quarter was -$0.52. Based on analyst estimates, the high estimate for the next quarter is -$0.17 and the low estimate is -$0.17. The average estimate for the next quarter is thus -$0.17.
